肿瘤-树突状细胞融合疫苗研究进展

Progress in Tumor-Dentritic Cell Hybrid Vaccines

树突状细胞(DC)是功能最强的专职抗原呈递细胞,在抗肿瘤免疫方面发挥着重要的作用.以DC为基础的肿瘤疫苗的研究发展迅速,其中效果最好的是DC/肿瘤融合细胞疫苗——不仅具有DC的抗原呈递功能,也持续产生内源性抗原肽.DC/肿瘤融合细胞疫苗不仅在动物实验中进行了大量的研究,而且已经进入了Ⅰ/Ⅱ期临床试验,结果表明,融合细胞能有效地诱导肿瘤特异性T淋巴细胞反应,病人也能很好地耐受.就DC/肿瘤融合疫苗的研究进展进行综述,并对目前研究中存在的问题作了客观的分析.

Dendritic cells （DCs） are the most potent professional APCs and play an important role in cancer immune response. With the rapid development of DC-based cancer vaccines, tumor-DC hybrids are the most effective ones —— they could present antigens and keep on producing endogenous antigens. The tumor-DC hybrids are currently being evaluated in many animal and clinical trials, available published data showed that hybrids could induce tumor specific T lymphocyte response and be well-tolerated in patients. The progress of tumor-DC hybrids, as well as some issues was discussed.